FDA Approved Gene Therapy for Sanfilippo Syndrome

The therapy offers a new path to stop the progression of Sanfilippo Syndrome Type A in children.

Updated on Sept. 23, 2026 in Allergies

Isometric editorial illustration of a glass medical vial containing a solution, representing a new medical breakthrough. — The FDA has approved UX111, a new gene therapy designed to stop the progression of Sanfilippo Syndrome Type A in children. AI Illustration. Upload story photo >

The US Food and Drug Administration has approved the gene therapy UX111, a treatment designed to halt the progression of Sanfilippo Syndrome Type A. The approval comes as families seek ways to access the multi-million dollar medical intervention.

Why it matters

This gene therapy provides a critical, disease-modifying option for a rare, neurodegenerative condition that previously lacked effective treatments. It highlights the growing complexity and financial burden families face when navigating newly approved, high-cost orphan drugs.

The treatment cost is set at £2.95 million per child, while families are currently working to meet fundraising goals for access. This therapy marks a significant advancement for patients with the rare, progressive condition.

The players

Tate Flaherty

He is a five-year-old child from Swansea, Wales, who was diagnosed with Sanfilippo Syndrome Type A.

US Food and Drug Administration

This is the federal agency responsible for protecting public health by ensuring the safety and efficacy of human drugs.

The details

The UX111 therapy is engineered to stop the progression of Sanfilippo Syndrome Type A, a devastating genetic disorder. Families, such as those represented by five-year-old patient Tate Flaherty, are currently navigating self-funding and insurance options to secure the treatment.

Tate Flaherty was diagnosed with the syndrome in September 2025.
The FDA approved the UX111 gene therapy in September 2026.
A charity football match for the patient was held at Pontardawe Football Club on September 27, 2026.

Allergies
Sept. 18
FDA Approved Fayuvi for Sanfilippo Syndrome Type A
Diabetes
Sept. 21
FDA Approved Gene Therapy for Glycogen Disorder
Biotech
Sept. 23
FDA Granted Breakthrough Status to Glycomine Drug

Health Landscape

The approval of UX111 follows the regulatory pathway established by the Orphan Drug Act to incentivize treatments for rare conditions. This development marks a transition toward gene therapies as the primary method for addressing previously incurable genetic syndromes.

The high cost of the therapy poses a significant financial challenge for families, who must rely on insurance or personal fundraising to afford the treatment. Patients and their guardians will need to work closely with specialized medical centers to determine eligibility and access.

The takeaway

While the approval of UX111 provides new hope for families battling Sanfilippo Syndrome Type A, the extreme cost necessitates careful financial and medical planning. Families should prioritize consulting with rare disease specialists to explore emerging funding assistance programs.